Clinical benefit rate of 73% reported in second line relapsed AML patients. Overall Response OOR 45%, CR/CRi rate of 36% Median treatment duration exceeding 6 months with some patients remaining on study Bergen, Norway, 6 DECEMBER 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, … Read more
Bergen, Norway, 3[ ]December 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that members of the management team will present the company at the following virtual conferences: The Nordic-American Life Science Conference Global Markets Day section Date: 3[rd] December 2020 … Read more
Bergen, Norway, 30 November 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce it has been accepted for a poster presentation at the 62[nd] Annual American Society of Hematology (ASH) Meeting, being held virtually from 5-8 December 2020. The poster will … Read more
Bergen, Norge – 24 november 2020: BerGenBio ASA (OSE: BGBIO), et biofarmasøytisk selskap i klinisk fase som utvikler nye, selektive hemmere av AXL-kinase for krefttyper med behov for forbedret behandlingstilbud, kunngjør i dag at den første pasienten har blitt rekruttert i selskapets fase-II klinisk studie (BGBC020), som vurderer effekten og sikkerheten til bemcentinib for behandling … Read more
Bergen, Norway – 24[th] November 2020: BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today announces that the first patient in India has been enrolled in the company sponsored Phase II clinical trial (BGBC020), assessing the efficacy and safety of bemcentinib for the treatment of … Read more
Bergen, Norge, 18 November 2020 – Det blir herved meldt at en ekstraordinær generalforsamling i BerGenBio ASA vil bli avholdt virtuelt 9 desember 2020 klokken 16.00 (CET). Innkalling, påmeldingsskjema og fullmakt er vedlagt dette skrivet. Innkallingen vil bli sendt til alle registrerte aksjonærer og er tilgengelig på https://www.bergenbio.com/investors/general- meetings/ (https://www.bergenbio.com/investors/general-%20meetings/) Alle aksjonærer oppfordres til å utøve sine … Read more
Bergen, Norway, 18 November 2020 – Notice is hereby given that an Extraordinary General Meeting in BerGenBio ASA will be held virtually on 9 December 2020 at 16:00 hours (CET). The notice, registration form and power of attorney are attached to this release. The notice will be sent to all registered shareholders and is available … Read more
Bergen, Norway, 17 November 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces its results for the third quarter of 2020. A presentation and live webcast by BerGenBio’s senior management will take place at 10.00 am CET today, please see below for details. Operational … Read more
Bergen, Norge, 11 November 2020 – BerGenBio ASA (OSE:BGBIO), et biofarmasøytisk selskap i klinisk fase som utvikler nye, selektive hemmere av AXL-kinase for krefttyper med behov for forbedret behandlingstilbud, vil i dag presentere en oppdatert klinisk og translasjonsanalyse fra sin fase-II bemcentinib og pembrolizumab kombinasjonsstudie (BGBC008) i ikke-småcellet lungekreft (NSCLC), under en muntlig presentasjon på den … Read more
Bergen, Norway, 11 November 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will today present an updated clinical & translational analysis from its Phase II bemcentinib and pembrolizumab combination study (BGBC008) in advanced non-small cell lung cancer (NSCLC), at an oral presentation at the … Read more
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.